Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

What We Do

In Our Own Words

Our work with clients, as well as through our partnerships with envelope-pushing, multi-stakeholder efforts such as the NEWDIGS LEAPS project and the Duke-Margolis RWE Collaborative, is helping to define the future of RWE in the healthcare space.

Oncology – An Exciting Time of New Hope and New Challenges Feature Image
Case Study

Embedded Qualitative Patient Interviews Support Regulatory Approval of Novel Oncology Treatment

Discover how Evidera’s Patient-Centered Research team helped to conduct embedded qualitative interviews that provided insights to lessen regulatory concerns about treatment side effects.

Read More
Case Study

Real-World Data Insights from LiveTracker® Determine Prescribing Trends for Cancers with High PD-L1 Protein Expression

Evidera's Real-World Data Solutions team used LiveTracker to evaluate HCP-reported data on treatment patterns in patients with non-small cell lung cancer and melanoma.

Read More
Case Study

Oncology Developer Utilizes Integrated Scientific Advice to Optimize Phase III Trial, Aligning Regulator and HTA Needs

Gain insight into how Evidera’s Value & Development Consulting team leveraged our Integrated Scientific Advice (ISA) offering to provide feedback to drug developers to optimize their evidence generation plans and satisfy stakeholder requirements.

Read More
Case Study

Six-Year Collaboration Across Six Indications for Groundbreaking Oncology Therapy

Evidera's Evidence Synthesis, Modeling & Communication team generated integrated packages of evidence, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models, for six indications.

Read More
Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety during the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Read More
Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Read More
Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More